Diagnostic Value of CT and MRI Combined with Serum LDH, NSE, CEA, and MYCN in Pediatric Neuroblastoma

Methods: Fifty-two children diagnosed with neuroblastoma were selected as the neuroblastoma group. During the same period, 52 children who visited our hospital with abdominal distension, diarrhea, constipation, and vomiting but were finally excluded from neuroblastoma were selected as the control group. CT and MRI were performed on all children.

Results: Fifty-two cases of neuroblastoma of the central nervous system were confirmed by pathological examination. The levels of LDH, NSE, CEA, and MYCN in the neuroblastoma group were clearly higher than those in the control group (P < 0.05). The results of CT and MRI combined with serum LDH, NSE, CEA, and MYCN were false positive in 10 cases and false negative in 6 cases, which were consistent with the pathological results. The sensitivity of CT and MRI combined with serum LDH, NSE, CEA, and MYCN in the diagnosis of neuroblastoma was notably higher than that of the three alone (P < 0.05).

Conclusion: The imaging findings of CT and MRI in children with central nervous system neuroblastoma were definitely characteristic. MRI had higher diagnostic value than CT. The diagnostic value of CT and MRI combined with serum LDH, NSE, CEA, and MYCN was improved to some extent.

Citing Articles

Stratification of Anatomical Imaging Features Between High-Risk and Non-High-Risk Groups in Neuroblastoma.

Wang H, Chen X, He L, Cai J Cancer Control. 2025; 32():10732748251315883.

PMID: 39833998 PMC: 11748161. DOI: 10.1177/10732748251315883.

References

Chen A, Trout A, Towbin A . A review of neuroblastoma image-defined risk factors on magnetic resonance imaging. Pediatr Radiol. 2018; 48(9):1337-1347. DOI: 10.1007/s00247-018-4117-9. View

Bedoya-Reina O, Li W, Arceo M, Plescher M, Bullova P, Pui H . Single-nuclei transcriptomes from human adrenal gland reveal distinct cellular identities of low and high-risk neuroblastoma tumors. Nat Commun. 2021; 12(1):5309. PMC: 8423786. DOI: 10.1038/s41467-021-24870-7. View

Al-Battashi A, Al-Rahbi A, Al-Rawahi A, Mamdouh M, Al-Ghaithi I, Ramadhan F . Neuroblastoma Among Omani Children: Clinical characteristics and survival outcome from a dedicated centre. Sultan Qaboos Univ Med J. 2021; 21(4):578-584. PMC: 8631225. DOI: 10.18295/squmj.4.2021.032. View

Alvi S, Karadaghy O, Manalang M, Weatherly R . Clinical manifestations of neuroblastoma with head and neck involvement in children. Int J Pediatr Otorhinolaryngol. 2017; 97:157-162. DOI: 10.1016/j.ijporl.2017.04.013. View

Boutroux H, Garel C, Jouannic J, Forin V, Mitanchez D, Fasola S . Neonatal dumbbell neuroblastoma: a case report, from prenatal diagnosis to postnatal strategy. J Pediatr Hematol Oncol. 2014; 37(4):328-9. DOI: 10.1097/MPH.0000000000000242. View

Chaturvedi A, Katzman P, Franco A . Neonatal neuroblastoma 4s with diffuse liver metastases (Pepper syndrome) without an adrenal/extraadrenal primary identified on imaging. J Radiol Case Rep. 2018; 12(3):18-27. PMC: 5965402. DOI: 10.3941/jrcr.v12i3.3300. View

Chu C, Rasalkar D, Hu Y, Cheng F, Li C, Chu W . Clinical presentations and imaging findings of neuroblastoma beyond abdominal mass and a review of imaging algorithm. Br J Radiol. 2010; 84(997):81-91. PMC: 3473807. DOI: 10.1259/bjr/31861984. View

Dore M, Mahe M, Corradini N, Demoor-Goldschmidt C . [Neonatal neuroblastoma complicated with a threatening tumoral hepatomegaly treated by irradiation: No sequel 20 years later]. Cancer Radiother. 2015; 19(8):749-51. DOI: 10.1016/j.canrad.2015.05.030. View

Gely L, Lugo-Vicente H, Correa-Rivas M, Bouet K, Reyes Bou Z, Suleiman M . Neonatal Sacrococcygeal Neuroblastoma Mimicking a Teratoma. Case Rep Pediatr. 2017; 2017:3624847. PMC: 5237461. DOI: 10.1155/2017/3624847. View

10.

Smith V, Foster J . High-Risk Neuroblastoma Treatment Review. Children (Basel). 2018; 5(9). PMC: 6162495. DOI: 10.3390/children5090114. View

11.

Swift C, Eklund M, Kraveka J, Alazraki A . Updates in Diagnosis, Management, and Treatment of Neuroblastoma. Radiographics. 2018; 38(2):566-580. DOI: 10.1148/rg.2018170132. View

12.

Alborzinia H, Florez A, Kreth S, Bruckner L, Yildiz U, Gartlgruber M . MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis. Nat Cancer. 2022; 3(4):471-485. PMC: 9050595. DOI: 10.1038/s43018-022-00355-4. View

13.

Chava S, Reynolds C, Pathania A, Gorantla S, Poluektova L, Coulter D . miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma. Mol Oncol. 2019; 14(1):180-196. PMC: 6944109. DOI: 10.1002/1878-0261.12588. View

14.

Durbin A, Wang T, Wimalasena V, Zimmerman M, Li D, Dharia N . EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified Neuroblastoma. Cancer Discov. 2021; 12(3):730-751. PMC: 8904277. DOI: 10.1158/2159-8290.CD-21-0385. View

15.

Li H, Li J, Chen L, Qi S, Yu S, Weng Z . HERC3-Mediated SMAD7 Ubiquitination Degradation Promotes Autophagy-Induced EMT and Chemoresistance in Glioblastoma. Clin Cancer Res. 2019; 25(12):3602-3616. DOI: 10.1158/1078-0432.CCR-18-3791. View

16.

Nakagawara A, Li Y, Izumi H, Muramori K, Inada H, Nishi M . Neuroblastoma. Jpn J Clin Oncol. 2018; 48(3):214-241. DOI: 10.1093/jjco/hyx176. View

17.

Takita J . Molecular Basis and Clinical Features of Neuroblastoma. JMA J. 2021; 4(4):321-331. PMC: 8580727. DOI: 10.31662/jmaj.2021-0077. View

18.

Ribeiro D, Klarqvist M, Westermark U, Oliynyk G, Dzieran J, Kock A . Regulation of Nuclear Hormone Receptors by MYCN-Driven miRNAs Impacts Neural Differentiation and Survival in Neuroblastoma Patients. Cell Rep. 2016; 16(4):979-993. DOI: 10.1016/j.celrep.2016.06.052. View